{"id":63561,"name":"ACURX PHARMACEUTICALS, INC.","slug":"acurx-pharmaceuticals-inc","state":"NY","country":"United States of America","description":"biopharmaceutical company","totalSpending":130000,"filings":6,"yearlySpending":[{"year":2024,"income":20000},{"year":2025,"income":110000}],"issues":[{"code":"BUD","display":"Budget/Appropriations"},{"code":"DEF","display":"Defense"}],"firms":["INNOVATIVE FEDERAL STRATEGIES, LLC"],"lobbyists":["ERYNN HOOK","CARL KIME","LETITIA WHITE"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Defense Threat Reduction Agency (DTRA)","Navy, Dept of"],"sampleDescriptions":["Research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.","H.R.____/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, 2026, Title II, all provisions related to research and clinical trials for the de","H.R.____/S.____, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.____/S.____, Departments of Labor, Health and Human Services, Educati","H.R.4026/S.____, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.____/S.____, Departments of Labor, Health and Human Services, Educati","H.R.____/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness."]}